Home

The INFINITY-SWEDEHEART RCT is a prospective, multicentre, single-blind, randomised study enrolling 2,400 patients at approximately 20 sites in Sweden treated with the DynamX bioadaptor in a 1:1 randomisation to Resolute Onyx (Medtronic) drug-eluting stent (DES). The study will utilise the SWEDEHEART registry database to support patient follow-up.

The primary endpoint of the study is a device-oriented clinical endpoint (DOCE) of non-inferiority of target lesion failure (TLF), a composite endpoint that includes cardiovascular death, target vessel myocardial infarction, and ischemia-driven target lesion revascularisation, at one year. Powered secondary endpoints include superiority in the overall population and pre-specified sub-groups, including small vessel, long lesions, left anterior descending artery (LAD), chronic angina and diabetes.

David Erlinge, Lund University, Lund, Sweden, is the principal investigator of the INFINITY-SWEDEHEART RCT, and Stefan James, Uppsala University Hospital, Uppsala, Sweden, chairs the Executive Steering Committee for the trial.

The DynamX bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to a DES. Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike DES. This has been shown to (a) maintain the ability for positive adaptive remodelling, (b) restore vessel function, and (c) allow for the vessel’s return toward baseline angulation.

The bioadaptor is designed to address the major adverse cardiac event (MACE) rate that occurs with drug-eluting stents each year without plateau. The rigid design of a DES constrains, or “cages,” natural artery movement, restricting its natural ability to accommodate disease progression. This has been associated with MACE.

Studies have shown adverse event rates associated with DES of 20% at five years and 40‒50% at 10 years. Published papers have demonstrated that a DES prevents positive adaptive remodeling, inhibits vessel compliance and dilation in response to the body’s changing blood flow needs, and causes vessel straightening, which has been associated with increased MACE.

“Drug-eluting stents have been very useful in opening blocked arteries, but the rigid stent structure cages the artery, impacting its ability to respond to disease progression and maintain blood flow lumen, as it would otherwise do naturally,” said Erlinge. “We are enthusiastic about studying the novel DynamX device, which is the first metallic device treating coronary artery disease that has been shown to restore pulsatility and positive adaptive remodelling of coronary arteries. The benefits of restored vessel function may provide greater benefit in patients with complex disease. The INFINITY-SWEDEHEART study includes these complex patients with both Chronic Coronary Syndrome and Acute Coronary Syndrome.”

“Swedish quality registries, including SWEDEHEART, have been utilised by Uppsala Clinical research center (UCR) for a number of groundbreaking cardiovascular clinical trials and it is appropriate that a unique device such as the DynamX device would be evaluated in a large number of patients using its infrastructure,” said James. “We have found the device as easy to deliver as a stent, but with the potential to reduce long-term DES-associated risks and improve upon patient outcomes over time.”

“The INFINITY-SWEDEHEART RCT utilising the respected SWEDEHEART registry database is an efficient approach to conducting an evidence-based trial, and provides important benefits. For the first time, we will be able to compare the performance of the physiologically-adaptive DynamX against an industry-leading DES in the overall study population and in subsets of patients. In addition, by leveraging the existing rigorous SWEDEHEART registry database, we will be able to conduct the trial and follow-up with high quality, efficiency and speed,” said Motasim Sirhan, Elixir Medical’s CEO.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua google bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua twitter bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua MySpace bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua LinkedIn bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua stumbleupon bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua icio bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua digg bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Chia sẽ qua yahoo bài: Elixir Medical commences INFINITY-SWEDEHEART randomised study of DynamX bioadaptor

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.